We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
Read MoreHide Full Article
Key Takeaways
Alvotech H1 2025 product revenues soared 200% YoY to nearly $205M, driven by immunology biosimilars.
The company entered ophthalmology with EU approval for Mynzepli, a biosimilar to Regeneron's Eylea.
Partnerships with Dr. Reddy's and Advanz expand ALVO into oncology and neurology biosimilars.
Alvotech (ALVO - Free Report) is rapidly scaling its presence in the biosimilar/generic market, thanks to its partnership-driven model. Under this approach, the company focuses on development and manufacturing, while its partners handle marketing and sales across key regions. By prioritizing alliances over a direct commercial footprint, Alvotech mitigates the risks associated with biosimilar launches and accelerates its ability to bring multiple products to market simultaneously.
The early momentum came from the company’s immunology biosimilars, including Simlandi (a biosimilar to AbbVie’s Humira) and Selarsdi (biosimilar to J&J’s Stelara), which are marketed in the United States through Teva Pharmaceuticals (TEVA - Free Report) . The company also has a similar partnership with Germany-based Stada to market both drugs across Europe. By leveraging the networks of an established partner like Teva, Alvotech has been able to scale adoption quickly and efficiently, without the financial burden of building an extensive sales infrastructure. In the first half of 2025, Alvotech’s product revenues surged more than 200% year over year to nearly $205 million.
Alvotech is also expanding beyond the immunology space. The company recently secured approval in the EU for Mynzepli, its biosimilar to Regeneron’s Eylea, through a partnership with Advanz Pharma. This marks its entry into ophthalmology, one of the fastest-growing therapeutic areas in the biosimilar landscape. Last month, the EMA’s Committee for Medicinal Products for Human Use recommended approval for the company’s regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and J&J’s Simponi.
To further diversify its market portfolio, the company has expanded its partnerships with Dr. Reddy’s Laboratories (RDY - Free Report) and Advanz Pharma to develop multiple biosimilar candidates across neurology and oncology. These include developing biosimilars for Novartis’ Kesimpta and Merck’s Keytruda, among others. Such strategic moves underscore how the company is leveraging its alliance-driven model not only to scale existing products but also to build a broader, multi-therapeutic portfolio that sustains top-line growth while remaining capital-efficient.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
Key Takeaways
Alvotech (ALVO - Free Report) is rapidly scaling its presence in the biosimilar/generic market, thanks to its partnership-driven model. Under this approach, the company focuses on development and manufacturing, while its partners handle marketing and sales across key regions. By prioritizing alliances over a direct commercial footprint, Alvotech mitigates the risks associated with biosimilar launches and accelerates its ability to bring multiple products to market simultaneously.
The early momentum came from the company’s immunology biosimilars, including Simlandi (a biosimilar to AbbVie’s Humira) and Selarsdi (biosimilar to J&J’s Stelara), which are marketed in the United States through Teva Pharmaceuticals (TEVA - Free Report) . The company also has a similar partnership with Germany-based Stada to market both drugs across Europe. By leveraging the networks of an established partner like Teva, Alvotech has been able to scale adoption quickly and efficiently, without the financial burden of building an extensive sales infrastructure. In the first half of 2025, Alvotech’s product revenues surged more than 200% year over year to nearly $205 million.
Alvotech is also expanding beyond the immunology space. The company recently secured approval in the EU for Mynzepli, its biosimilar to Regeneron’s Eylea, through a partnership with Advanz Pharma. This marks its entry into ophthalmology, one of the fastest-growing therapeutic areas in the biosimilar landscape. Last month, the EMA’s Committee for Medicinal Products for Human Use recommended approval for the company’s regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and J&J’s Simponi.
To further diversify its market portfolio, the company has expanded its partnerships with Dr. Reddy’s Laboratories (RDY - Free Report) and Advanz Pharma to develop multiple biosimilar candidates across neurology and oncology. These include developing biosimilars for Novartis’ Kesimpta and Merck’s Keytruda, among others. Such strategic moves underscore how the company is leveraging its alliance-driven model not only to scale existing products but also to build a broader, multi-therapeutic portfolio that sustains top-line growth while remaining capital-efficient.